Nodality, Inc. Announces Publication Of Promising Data In Melanoma In Journal Of Translational Medicine

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., an innovative biotechnology company advancing discovery, development and use of transformative therapies by revealing functional systems biology, announced today promising data utilizing the company's proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma. Nodality’s SCNP technology reveals functional biology underlying the most important and intractable diseases, providing critical insights to help guide the discovery and development of next-generation therapeutic agents. According to data published in the current issue of the Journal of Translational Medicine (JTM), Nodality’s researchers have identified key biomarkers in the blood that can help predict responses to new therapies for melanoma, including cancer immunotherapeutics.

Help employers find you! Check out all the jobs and post your resume.